<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03915769</url>
  </required_header>
  <id_info>
    <org_study_id>RPC01-3103</org_study_id>
    <secondary_id>U1111-1230-3228</secondary_id>
    <nct_id>NCT03915769</nct_id>
  </id_info>
  <brief_title>To Evaluate Efficacy and Long-term Safety of Ozanimod in Japanese Subjects With Moderately to Severely Active Ulcerative Colitis</brief_title>
  <official_title>A Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of Oral Ozanimod to Evaluate Efficacy and Long-term Safety in Japanese Subjects With Moderately to Severely Active Ulcerative Colitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celgene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celgene</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Japanese patients with moderate or severe active ulcerative colitis as a subject when
      ozanimod 0.46 mg or 0.92 mg is orally administered is evaluated about dose response, efficacy
      and safety with placebo as a control.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Following the 4-week Screening Period, eligible subjects will be randomized to enter the 12
      weeks placebo-controlled Induction Period (IP). Subjects who are responders at Week 12 will
      continue on their assigned treatment in the 52-week Maintenance Period (MP). Non responders
      at Week 12 have the option to enter the Open-label Extension (OLE). Subjects who complete the
      MP will be given the option to participate in the OLE. Subjects that enter the MP and
      experience disease relapse will also have the option to enter the OLE. The OLE will continue
      until marketing launch (about 4 years of ozanimod for Ulcerative colitis (UC), or until the
      Sponsor discontinues the development program.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 3, 2019</start_date>
  <completion_date type="Anticipated">October 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 23, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects with clinical response</measure>
    <time_frame>At Week 12</time_frame>
    <description>Defined as a reduction from Baseline in the complete Mayo score of ≥ 3 points and ≥ 30%, and a reduction from Baseline in the rectal bleeding subscore of ≥ 1 point or an absolute rectal bleeding subscore of ≤ 1 point</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with clinical remission</measure>
    <time_frame>At Week 12 and Week 52</time_frame>
    <description>Defined as: Definition 1. Complete Mayo score of ≤ 2 points with no individual subscore of &gt; 1 point, Definition 2. Rectal bleeding subscore = 0 and stool frequency subscore ≤ 1 (and a decrease of ≥ 1 point from the Baseline stool frequency subscore) and endoscopy subscore ≤ 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects in clinical remission measured at week 12- Rectal Bleeding</measure>
    <time_frame>Up to week 12</time_frame>
    <description>Defined as Rectal bleeding subscore = 0 and stool frequency subscore ≤ 1 (and a decrease of ≥ 1 point from the Baseline stool frequency subscore) and endoscopy subscore ≤ 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with endoscopic improvement</measure>
    <time_frame>At Week 12 and Week 52</time_frame>
    <description>Defined as an endoscopy subscore of ≤ 1 point</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with mucosal healing</measure>
    <time_frame>At Week 12 and Week 52</time_frame>
    <description>Defined as an endoscopy subscore of ≤ 1 point and a Geboes index score &lt; 2.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with a clinical response</measure>
    <time_frame>At Week 9</time_frame>
    <description>Defined as a reduction from Baseline in the partial Mayo score of ≥ 2 points and ≥ 30%, and a reduction from Baseline in the rectal bleeding subscore of ≥ 1 point or an absolute rectal bleeding subscore of ≤ 1 point</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the EuroQol-5 Dimension (EQ-5D) from baseline</measure>
    <time_frame>At Week 12</time_frame>
    <description>Is a quality of life questionnaires and will be collected from all subjects at visits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects in clinical remission measured at week 52 - Mayo Score</measure>
    <time_frame>Up to week 52</time_frame>
    <description>Complete Mayo score of ≤ 2 points with no individual subscore of &gt; 1 point</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subject with clinical response</measure>
    <time_frame>At week 52</time_frame>
    <description>Defined as a reduction from Baseline in the complete Mayo score of ≥ 3 points and ≥ 30%, and a reduction from Baseline in the rectal bleeding subscore of ≥ 1 point or an absolute rectal bleeding subscore of ≤ 1 point</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects in remission while off corticosteroids for any length of time</measure>
    <time_frame>Up to week 52</time_frame>
    <description>Proportion of subjects in remission while off corticosteroids for any length of time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in partial Mayo score from Baseline</measure>
    <time_frame>Up to week 64</time_frame>
    <description>Change in partial Mayo score from Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Event (AE)</measure>
    <time_frame>From enrollment until at least 75 days after completion of study treatment</time_frame>
    <description>Number of participants with adverse event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects in clinical remission measured at week 52- Rectal Bleeding</measure>
    <time_frame>Up to week 52</time_frame>
    <description>Defined as an endoscopy subscore of ≤ 1 point</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subject with clinical response at week 52</measure>
    <time_frame>Up to week 52</time_frame>
    <description>Defined as a reduction from Baseline in the complete Mayo score of ≥ 3 points and ≥ 30%, and a reduction from Baseline in the rectal bleeding subscore of ≥ 1 point or an absolute rectal bleeding subscore of ≤ 1 point</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with endoscopic improvement</measure>
    <time_frame>Up to week 52</time_frame>
    <description>Defined as an endoscopy subscore of ≤ 1 point</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with mucosal healing</measure>
    <time_frame>Up to week 52</time_frame>
    <description>Defined as an endoscopy subscore of ≤ 1 point and a Geboes index score &lt; 2.0</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">195</enrollment>
  <condition>Colitis, Ulcerative</condition>
  <arm_group>
    <arm_group_label>0.46 mg ozanimod oral capsule once daily (QD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>It will be a 7-day dose escalation regimen in the IP consisting of 4 days of treatment with 0.23 mg ozanimod, followed by 3 days of treatment with 0.46 mg ozanimod, followed by 0.46 mg ozanimod.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.92 mg ozanimod oral capsule QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>It will be a 7-day dose escalation regimen in the IP consisting of 4 days of treatment with 0.23 mg ozanimod, followed by 3 days of treatment with 0.46 mg ozanimod, followed by 0.92 mg ozanimod.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo oral capsule QD</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>It will be a 7-day dose escalation regimen in the IP consisting of 4 days of treatment with a placebo capsule, followed by 3 days of treatment with two placebo capsules, followed by two placebo capsules.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ozanimod</intervention_name>
    <description>Ozanimod is an orally bioavailable, small molecule compound that activates the sphingosine 1-phosphate 1 receptor (S1P1) and the S1P 5 receptor (S1P5), although it is more selective towards S1P1 over S1P5</description>
    <arm_group_label>0.46 mg ozanimod oral capsule once daily (QD)</arm_group_label>
    <arm_group_label>0.92 mg ozanimod oral capsule QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The placebo is a capsule that contains no study medication but looks exactly like the study medication capsule.</description>
    <arm_group_label>Placebo oral capsule QD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Main Inclusion Criteria for Induction and Maintenance Periods

          1. Subject is a Japanese male or female subjects aged 18 to 75 years at the time of
             signing the informed consent form (ICF) at Screening.

          2. Subject has had Ulcerative Colitis (UC) diagnosed at least 3 months prior to first
             investigational product administration. The diagnosis should be confirmed by clinical
             and endoscopic evidence and corroborated by a histopathology report.

          3. Subject has evidence of UC extending ≥ 15 cm from the anal verge as determined by
             Baseline endoscopy (flexible sigmoidoscopy or colonoscopy).

          4. Subject has active UC defined as Mayo score of 6 to 12 inclusive, with endoscopic
             subscore of ≥ 2, a rectal bleeding score of ≥ 1, and a stool frequency score ≥ 1.

        Main Inclusion Criteria for Open-label Extension Period

        Subjects must satisfy the following criteria to be enrolled in the study:

        1. Subject must have completed through the Week 12 Visit in the Induction Period (IP) AND
        either:

          -  Completed participation through the last study treatment visit at Week 64 and
             maintained clinical response in the Maintenance Period (MP), OR

          -  Experiencing disease relapse eligible for Open-label Extension (OLE).

        Exclusion Criteria:

        Main Exclusion Criteria

          1. Subject has severe extensive colitis

          2. Subject has diagnosis of Crohn's disease or indeterminate colitis or the presence or
             history of a fistula consistent with Crohn's disease or microscopic colitis or
             radiation colitis or ischemic colitis.

          3. Subject has positive stool examination for pathogens (ova and parasites, bacteria) or
             positive test for toxin producing Clostridium difficile (C. difficile) at Screening.4.
             Subject is pregnant or breastfeeding

        5. Subject has clinically relevant cardiovascular conditions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ben Hatano, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Celgene</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eijiro Higashi</last_name>
    <phone>+81-3-5224-0892</phone>
    <email>ehigashi@celgene.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Aya Nagshima</last_name>
    <phone>+81-3-5224-0788</phone>
    <email>anagashima@celgene.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kokikai Tokatsu-Tsujinaka Hospital</name>
      <address>
        <city>Abiko</city>
        <zip>270-1168</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mazda Hospital of Mazda Motor Corporation</name>
      <address>
        <city>Aki-gun</city>
        <zip>735-8585</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical Hospital of Tokyo Medical and Dental University</name>
      <address>
        <city>Bunkyo-ku, Tokyo</city>
        <zip>113-8519</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fukuoka University Chikushi Hospital</name>
      <address>
        <city>Chikushino</city>
        <zip>818-8502</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sai Clinic</name>
      <address>
        <city>Fujiidera</city>
        <zip>538-0027</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fukui Prefectural Hospital</name>
      <address>
        <city>Fukui</city>
        <zip>910-8526</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fukui-ken Saiseikai Hospital</name>
      <address>
        <city>Fukui</city>
        <zip>918-8503</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gifu Prefectural General Medical Center</name>
      <address>
        <city>Gifu</city>
        <zip>500-8717</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hakodate Goryokaku Hospital</name>
      <address>
        <city>Hakodate</city>
        <zip>040-8611</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hirosaki University Hospital</name>
      <address>
        <city>Hirosaki</city>
        <zip>036-8203</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hiroshima University Hospital</name>
      <address>
        <city>Hiroshima</city>
        <zip>734-8551</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hitachi General Hospital</name>
      <address>
        <city>Hitachi, Ibaraki</city>
        <zip>317-0077</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Saitama Medical University Hospital</name>
      <address>
        <city>Iruma-gun</city>
        <zip>350-0495</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tokai University Hospital</name>
      <address>
        <city>Isehara City, Kanagawa</city>
        <zip>259-1193</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kanazawa Medical University Hospital</name>
      <address>
        <city>Kahoku-gun</city>
        <zip>920-0293</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mitoyo General Hospital</name>
      <address>
        <city>Kannonji</city>
        <zip>769-1695</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nara Medical University Hospital</name>
      <address>
        <city>Kashihara</city>
        <zip>634-8522</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kobe University Hospital</name>
      <address>
        <city>Kobe</city>
        <zip>650-0017</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Komatsu Municipal Hospital</name>
      <address>
        <city>Komatsu</city>
        <zip>923-8560</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hoshi General Hospital</name>
      <address>
        <city>Koriyama</city>
        <zip>963-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kurume University Hospital</name>
      <address>
        <city>Kurume, Fukuoka</city>
        <zip>830-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Our Lady of the Snow Social Medical Corporation St. Mary's Hospital</name>
      <address>
        <city>Kurume</city>
        <zip>830-8543</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital, Kyoto Prefectural University of Medicine</name>
      <address>
        <city>Kyoto-city</city>
        <zip>602-8566</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ehime Prefectural Central Hospital</name>
      <address>
        <city>Matsuyama</city>
        <zip>790-0024</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Jikei University Hospital</name>
      <address>
        <city>Minato-ku</city>
        <zip>105-8471</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kitasato University Kitasato Institute Hospital</name>
      <address>
        <city>Minato-ku</city>
        <zip>108-8642</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kyorin University Hospital</name>
      <address>
        <city>Mitaka</city>
        <zip>181-8611</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Iwate Medical University Uchimaru Medical Center</name>
      <address>
        <city>Morioka</city>
        <zip>020-8505</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nagaoka Chuo General Hospital</name>
      <address>
        <city>Nagaoka</city>
        <zip>940-8653</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hyogo College of Medicine Hospital</name>
      <address>
        <city>Nishinomiya</city>
        <zip>663-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ogaki Municipal Hospital</name>
      <address>
        <city>Ogaki</city>
        <zip>503-8502</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Okayama Saiseikai Outpatient Center Hospital</name>
      <address>
        <city>Okayama</city>
        <zip>700-0013</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Osaka City University Hospital</name>
      <address>
        <city>Osaka</city>
        <zip>545-8586</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Osaki Citizen Hospital</name>
      <address>
        <city>Osaki-shi</city>
        <zip>989-6183</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shiga University of Medical Science Hospital</name>
      <address>
        <city>Otsu</city>
        <zip>520-2192</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tokitokai Tokito Clinic</name>
      <address>
        <city>Saitama</city>
        <zip>336-0963</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Osaka Rosai Hospital</name>
      <address>
        <city>Sakai</city>
        <zip>591-8025</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Toho University Medical Center Sakura Hospital</name>
      <address>
        <city>Sakura</city>
        <zip>285-8741</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sapporo Medical University Hospital</name>
      <address>
        <city>Sapporo, Hokkaidô</city>
        <zip>060-8543</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>JA Sapporo Kosei General Hospital</name>
      <address>
        <city>Sapporo</city>
        <zip>060-0033</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Japan Community Health care Organization Hokkaido Hospital</name>
      <address>
        <city>Sapporo</city>
        <zip>062-8618</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>IMS Meirikai Sendai General Hospital</name>
      <address>
        <city>Sendai</city>
        <zip>980-0021</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NTT Medical Center Tokyo</name>
      <address>
        <city>Shinagawa-ku, Tokyo</city>
        <zip>141-8625</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tokyo Yamate Medical Center</name>
      <address>
        <city>Shinju-ku</city>
        <zip>169-0073</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shizuoka City Shizuoka Hospital</name>
      <address>
        <city>Shizuoka-shi</city>
        <zip>420-8630</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Shizuoka Medical Center</name>
      <address>
        <city>Sunto-gun</city>
        <zip>411-8611</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kagawa Prefectural Central Hospital</name>
      <address>
        <city>Takamatsu</city>
        <zip>760-8557</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical Corporation Shoyu-Kai Fujita Gastroenterology Hospital</name>
      <address>
        <city>Takatsuki</city>
        <zip>569-0086</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Takatsuki Red Cross Hospital</name>
      <address>
        <city>Takatsuki</city>
        <zip>569-1096</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Toyama City Hospital</name>
      <address>
        <city>Toyama</city>
        <zip>939-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mie University hospital</name>
      <address>
        <city>Tsu</city>
        <zip>514-8507</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kanke Gastrointestinal Clinic</name>
      <address>
        <city>Utsunomiya</city>
        <zip>320-0003</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 12, 2019</study_first_submitted>
  <study_first_submitted_qc>April 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 16, 2019</study_first_posted>
  <last_update_submitted>April 6, 2020</last_update_submitted>
  <last_update_submitted_qc>April 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ulcerative colitis</keyword>
  <keyword>Ozanimod</keyword>
  <keyword>colitis</keyword>
  <keyword>Ulcerative</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>https://www.celgene.com/research-development/clinical-trials/clinical-trials-data-sharing/</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>See Plan Description</ipd_time_frame>
    <ipd_access_criteria>See Plan Description</ipd_access_criteria>
    <ipd_url>https://www.celgene.com/research-development/clinical-trials/clinical-trials-data-sharing/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

